ENSEM is pleased to announce the promotion of Shengfang Jin, PhD to President & CEO. Read More

Shengfang Jin, co-founder, President and CSO of ENSEM Therapeutics, has been featured in the ENSEM launch announcement through Endpoints News, an independent news organization that reports and analyzes the top global biotech and pharmaceutical R&D news of the day. Read More

ENSEM Therapeutics is proud to announce our Series A funding of $67 million to further advance our Kinetic Ensemble^TM platform and accelerate R&D pipeline. Read More